- Report
- November 2023
- 130 Pages
Global
From €4318EUR$4,500USD£3,734GBP
- Report
- February 2024
- 200 Pages
Global
From €4797EUR$5,000USD£4,148GBP
- Report
- May 2024
- 179 Pages
Global
From €5229EUR$5,450USD£4,522GBP
- Report
- April 2024
- 137 Pages
Global
From €3741EUR$3,899USD£3,235GBP
- Clinical Trials
- April 2024
- 240 Pages
Global
From €2878EUR$3,000USD£2,489GBP
- Report
- August 2023
- 146 Pages
Global
From €2399EUR$2,500USD£2,074GBP
- Report
- July 2023
- 224 Pages
Global
From €4728EUR$5,100USD£3,950GBP
- Report
- February 2024
- 175 Pages
Global
From €4797EUR$5,000USD£4,148GBP
- Clinical Trials
- April 2024
- 240 Pages
Global
From €2878EUR$3,000USD£2,489GBP
- Report
- October 2023
- 38 Pages
Global
From €3833EUR$3,995USD£3,315GBP
- Report
- October 2023
- 146 Pages
Global
From €3385EUR$3,528USD£2,927GBP
€3982EUR$4,150USD£3,443GBP
- Newsletter
- May 2024
Global
From €1010EUR$1,128USD£904GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4749EUR$4,950USD£4,107GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4749EUR$4,950USD£4,107GBP
- Report
- August 2018
- 197 Pages
Global
From €3454EUR$3,600USD£2,987GBP
- Report
- January 2020
- 18 Pages
Global
From €2878EUR$3,000USD£2,489GBP
- Report
- March 2021
- 210 Pages
Global
From €2303EUR$2,400USD£1,991GBP
- Report
- January 2023
- 130 Pages
Global
From €2159EUR$2,250USD£1,867GBP
- Report
- February 2023
- 199 Pages
Global
From €5325EUR$5,550USD£4,605GBP
- Report
- April 2022
- 178 Pages
Global
From €3056EUR$3,185USD£2,643GBP
€4366EUR$4,550USD£3,775GBP
Non Alcoholic Steatohepatitis (NASH) Drug market is a subset of the Liver and Kidney Disorders Drugs market. NASH is a chronic liver disease caused by the accumulation of fat in the liver, leading to inflammation and scarring. It is a major cause of cirrhosis and liver failure. The NASH Drug market is driven by the increasing prevalence of NASH, rising awareness of the disease, and the availability of new treatments.
The NASH Drug market is segmented by drug class, including biologics, small molecules, and others. Biologics are the most widely used drugs for NASH, as they target specific pathways involved in the disease. Small molecules are also used to treat NASH, as they are more cost-effective and have fewer side effects.
The NASH Drug market is highly competitive, with many companies developing new treatments. Some of the major players in the market include Gilead Sciences, Intercept Pharmaceuticals, Allergan, Novartis, and Genfit. Show Less Read more